EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma

Julie A Tomolonis, Xin Xu iD, Kshiti H Dholakia iD, Chunchao Zhang, Linjie Guo, Amy N Courtney, Siyue Wang, Julien Balzeau, Gabriel A Barragán, Gengwen Tian, Erica J Di Pierro, Leonid S Metelitsa iD

Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e005478

DOI: 10.1136/jitc-2022-005478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.03.2023. Verfasst von Julie A Tomolonis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Receptors, Tumor Necrosis Factor, Type II, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Robert and Janice McNair Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor progression and resistance to therapy in children with neuroblastoma (NB), a common childhood cancer, are often associated with infiltration of monocytes and macrophages that produce inflammatory cytokines. However, the mechanism by which tumor-supportive inflammation is initiated and propagated remains unknown. Here, we describe a novel protumorigenic circuit between NB cells and monocytes that is triggered and sustained by tumor necrosis factor alpha (TNF-α).

Methods

We used NB knockouts (KOs) of TNF-α and TNFRSF1A mRNA (TNFR1)/ TNFRSF1B mRNA (TNFR2) and TNF-α protease inbitor (TAPI), a drug that modulates TNF-α isoform expression, to assess the role of each component in monocyte-associated protumorigenic inflammation. Additionally, we employed NB-monocyte cocultures and treated these with clinical-grade etanercept, an Fc-TNFR2 fusion protein, to neutralize signaling by both membrane-bound (m) and soluble (s)TNF-α isoforms. Further, we treated NOD/SCID/IL2Rγ(null) mice carrying subcutaneous NB/human monocyte xenografts with etanercept and evaluated the impact on tumor growth and angiogenesis. Gene set enrichment analysis (GSEA) was used to determine whether TNF-α signaling correlates with clinical outcomes in patients with NB.

Results

We found that NB expression of TNFR2 and monocyte membrane-bound tumor necrosis factor alpha is required for monocyte activation and interleukin (IL)-6 production, while NB TNFR1 and monocyte soluble TNF-α are required for NB nuclear factor kappa B subunit 1 (NF-κB) activation. Treatment of NB-monocyte cocultures with clinical-grade etanercept completely abrogated release of IL-6, granulocyte colony-stimulating factor (G-CSF), IL-1α, and IL-1β and eliminated monocyte-induced enhancement of NB cell proliferation in vitro. Furthermore, etanercept treatment inhibited tumor growth, ablated tumor angiogenesis, and suppressed oncogenic signaling in mice with subcutaneous NB/human monocyte xenografts. Finally, GSEA revealed significant enrichment for TNF-α signaling in patients with NB that relapsed.

Conclusions

We have described a novel mechanism of tumor-promoting inflammation in NB that is strongly associated with patient outcome and could be targeted with therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaAnimalsHumansMiceCarcinogenesisEtanerceptMice, Inbred NODMice, SCIDMonocytesReceptors, Tumor Necrosis Factor, Type I

Stichwörter der Autor:innen

InflammationMacrophagesNeuroblastoma

Substanzen

EtanerceptReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Medical Scientist Training Program (MSTP), Baylor College of Medicine, Houston, Texas, USA.
  • Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA lsmeteli@texaschildrens.org.
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
  • Center for Cell and Gene Therapy, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Xin Xu, Kshiti H Dholakia, Leonid S Metelitsa

Förderung

  • NCI NIH HHS
  • Robert and Janice McNair Foundation
  • National Institutes of Health
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Tomolonis, J. A., Xu, X., Dholakia, K. H., Zhang, C., Guo, L., Courtney, A. N., Wang, S., Balzeau, J., Barragán, G. A., Tian, G., Di Pierro, E. J., & Metelitsa, L. S. (2023). Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma. Journal for ImmunoTherapy of Cancer, 11(3), e005478. https://doi.org/10.1136/jitc-2022-005478

Vancouver

Tomolonis JA, Xu X, Dholakia KH, Zhang C, Guo L, Courtney AN, et al. Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma. Journal for ImmunoTherapy of Cancer. 2023;11(3):e005478. doi:10.1136/jitc-2022-005478

BibTeX
@article{Tomolonis2023,
  author = {Tomolonis, Julie A and Xu, Xin and Dholakia, Kshiti H and Zhang, Chunchao and Guo, Linjie and Courtney, Amy N and Wang, Siyue and Balzeau, Julien and Barragán, Gabriel A and Tian, Gengwen and Di Pierro, Erica J and Metelitsa, Leonid S},
  title = {Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {e005478},
  doi = {10.1136/jitc-2022-005478}
}
Kostenlos starten →